Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan

Mumtaz, Khalid; Salehiniya, Hamid; Adil, Salman Naseem; Afaq, Asim; Islam, Muhammad; Abid, Shahab; Shah, Hasnain Ali; Jafri, Wasim

doi:10.1111/j.1440-1746.2005.03857.x

Cited by 70 publications

(67 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDV appears to be endemic in the Middle East. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide (Mumtaz et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

Ahmed¹,

Sheemy²,

Sedky³

et al. 2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Hepatitis D virus (HDV) is a defectivevirus thatrequires the presence of hepatitis B virus (HBV) for infection. It has been estimated that approximately 5% of the global hepatitis B surface antigen (HBsAg) carriers are also co-infected with HDV, leading to a total of 10-15 million HDV carriers worldwide. In the current study, we investigated anti-HDV seroprevalance, epidemiological features and effect of HDV on HBV morbidity and presence ofHBe antigen markers among 216 HBsAg seropositive patients recruited from four hospitals in Egypt between October 2009 and October 2011. Anti-HDV assay was performed by enzyme immunoassay (EIA). Then, the HDV seropositive patients were further investigated for HBe antigen and antibody, HBV DNA and HBV genotyping.Out of 216 HBsAg positive patients, 32 (14.8%) were anti-HDV positive. This study confirmed a declining trend in the prevalence of HDV infection in Egypt. A suppressive effect of HDV on HBV replication was suggested from the lower rate of detection of HBeAg (3.13%), which is indirectly proportional to viral replication, and the higher rate of detection of HBeAb (75%) in anti-HDV positive patients.

show abstract

“…HDV appears to be endemic in the Middle East. A decline in the prevalence of both acute and chronic hepatitis D (CHD) has been observed worldwide (Mumtaz et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

Ahmed¹,

Sheemy²,

Sedky³

et al. 2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

show abstract

“…In a large series, hepatitis D virus (HDV) antibodies in HBsAg positive individuals were found to be present in 16.6% cases [2] . So there is a large pool of patients exposed to hepatitis D in this country.…”

Section: Introductionmentioning

confidence: 99%

Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial

Abbas

Memon

Umer

et al. 2016

WJH

View full text Add to dashboard Cite

AIM:To investigate the efficacy of pegylated interferon alfa (PEG-IFNα) therapy with and without entecavir in patients with chronic hepatitis D. METHODS:Forty hepatitis D virus (HDV) RNA positive patients were randomized to receive either PEG-IFNα-2a 180 µg weekly in combination with entecavir 0.5 mg daily (n = 21) or PEG-IFNα alone (n =19). Patients who failed to show 2 log reduction in HDV RNA level at 24 wk of treatment, or had detectable HDV RNA at 48 wk of therapy were considered as treatment failure. Treatment was continued for 72 wk in the rest of the patients. All the patients were followed for 24 wk post treatment. Intention to treat analysis was performed. RESULTS:The mean age of the patients was 26.7 ± 6.8 years, 31 were male. Two log reduction in HDV RNA levels at 24 wk of therapy was achieved in 9 (43%) patients receiving combination therapy and 12 (63%) patients receiving PEG-IFNα alone (P = 0.199). Decline in hepatitis B surface antigen (HBsAg) levels was insignificant. At the end of treatment, HDV RNA was negative in 8 patients (38%) receiving combination Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial Randomized Clinical Trial ORIGINAL ARTICLEtherapy and 10 patients (53%) receiving PEG-IFNα-2a alone. Virological response persisted in 7 (33%) and 8 (42%) patients, respectively at the end of the 24 wk follow-up period. One responder patient in the combination arm lost HBsAg and became hepatitis B surface antibody positive. Six out of 14 baseline hepatitis B e antigen reactive patients seroconverted and four of these seroconverted patients had persistent HDV RNA clearance. CONCLUSION:Administration of PEG-IFNα-2a with or without entecavir, resulted in persistent HDV RNA clearance in 37% of patients. The addition of entecavir did not improve the overall response.

show abstract

“…The study also revealed the presence of HDV antibodies in 21.4% of HBV undetectable viral load. Hence, it is important to look for HVD even at a low viral load, as highlighted by the work of Beata Lorenc and colleagues in Poland in 2016 (Mumtaz et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Exploratory study of hepatitis D virus infection in HBsAg carriers in Abidjan, Cte Divoire in 2016

Sévédé¹,

Doumbia²,

Kouakou³

et al. 2018

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

show abstract

Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan

Abstract: (i) HDV infection is present in 16.6% of hepatitis B infected patients in Pakistan, most commonly in younger males living in rural areas; and (ii) delta virus infected patients have less severe clinical liver disease compared to delta negative, hepatitis B patients.

Cited by 70 publications

References 18 publications

Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial

Exploratory study of hepatitis D virus infection in HBsAg carriers in Abidjan, Cte Divoire in 2016

Contact Info

Product

Resources

About